Health Care Professional Alert card for NHL/CLL addressing the correct route of administration for Rixathon®

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See 'further information' section for how to report adverse reactions.

For Rixathon®:

Rixathon® is intended for INTRAVENOUS administration ONLY –

NOT for SUBCUTANEOUS use

Other rituximab products for subcutaneous use are available on the market.

FOR INTRAVENOUS INFUSION

Rixathon® 100 mg / 10 ml concentrate for solution for infusion

Rixathon® 500 mg / 50 ml concentrate for solution for infusion

For intravenous use in all Rixathon® - approved indications

Dilute with 0.9% NaCl or 5% Glucose and administer by intravenous infusion.

Further information:

Consult the Product Information before prescribing, preparing or administering Rixathon®
SPC is available on request from Rowex Ltd. or on the HPRA website.
Suspected adverse reaction should be reported to the HPRA at www.hpra.ie or to Rowex Ltd. Bantry, Co. Cork; email: pv@rowa-pharma.ie or phone 027 50077